PUR3100

About Pulmatrix

Pulmatrix is dedicated to improving the lives of patients with severe respiratory and other diseases through its innovative dry powder inhalation platform, iSPERSE™. This technology allows for high drug loads, efficient lung delivery, and stable formulations of challenging compounds. The company's lead program, PUR3100, is an inhaled dihydroergotamine (DHE) in development for acute migraine, representing a novel, non-systemic treatment approach. Pulmatrix's strategy includes advancing its proprietary pipeline and pursuing strategic collaborations to leverage its platform.

Therapeutic Areas